Use the GLP-1 offer
Likeness Rx has different service pages. This review uses the GLP-1 plan page, not the general skincare homepage. The page checked October 5, 2026 lists monthly compounded semaglutide at $139 and tirzepatide at $199. It also presents longer commitments whose total and monthly equivalent differ from a month-to-month arrangement.
Make the arithmetic visible
The semaglutide offer lists $327 for three months, $534 for six and $948 for twelve. Corresponding tirzepatide totals are $477, $834 and $1,548. Dividing a term total by its month count gives a comparison figure; it does not make the total payable one month at a time. Confirm the actual payment schedule before choosing a longer term.
Read the policy alongside the price
The GLP-1 page describes renewal for the selected term and an early first-refill charge. The advertised refund if medication is not prescribed has a particular condition; it should not be converted into a general money-back promise after treatment begins. Save the terms relevant to the plan rather than relying on an isolated price tile.
Keep product verification specific
A pharmacy named for a separate skincare service is not automatically the pharmacy for a GLP-1 order. Ask which pharmacy will dispense your preparation and how its label can be verified. Compounded medicines do not have FDA approval, and a provider advertisement does not supply an independent quality assessment.
Likeness occupies promotional position three because the publisher selected it. We may earn compensation from links. We have not purchased a plan, tested support or assessed patient outcomes. This dossier makes the public terms easier to inspect; it does not resolve an individual's clinical suitability or certify the service.
Source notes
Checked October 5, 2026. Provider pages document advertised terms. Study summaries identify the scope of our review.
- Likeness Rx — GLP-1 plansProvider offer and renewal terms
- FDA — compounding questions and answersCompounded-product status
- FDA — concerns with unapproved GLP-1 drugsRegulatory and safety context